Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy
BackgroundTo date, the non-viral vector Chimeric Antigen Receptor (CAR) T cell preparation platform, exemplified by transposons, has demonstrated significant potential in tumor immunotherapy and yielded positive results in multiple clinical trials. Non…